Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/ HER2-) metastatic breast cancer (BC) Meeting Abstract
| Authors: | Bedard, P. L.; Accordino, M. K.; Cervantes, A.; Gambardella, V.; Hamilton, E. P.; Italiano, A.; Juric, D.; Kalinsky, K.; Krop, I. E.; Oliveira, M.; Saura, C.; Schmid, P.; Turner, N. C.; Varga, A.; Shankar, N.; Schutzman, J.; Royer Joo, S.; Martin, M. V.; Jhaveri, K. L. |
| Abstract Title: | Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/ HER2-) metastatic breast cancer (BC) |
| Meeting Title: | 2022 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 16 Suppl. |
| Meeting Dates: | 2022 Jun 3-7 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-06-01 |
| Language: | English |
| ACCESSION: | WOS:000863680300133 |
| PROVIDER: | wos |
| DOI: | 10.1200/JCO.2022.40.16_suppl.1052 |
| Notes: | Meeting Abstract: 1052 -- This meeting was also held virtually -- Source: Wos |
